Please assess the completion status of the following clinical trial:

Trial Title: COVAXIN in a Pediatric Cohort

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide written informed consent (by the parents or legally acceptable/authorized representative (LAR) and assent by the children (verbal/oral assent for the children of age between 7-12 years, and written assent for the children of age between \>12 to 18 years), and Audio video consent for all participants.~2. Participants of either gender of age between ≥2 to ≤18years (Participant should be ≤18 years at the time of Screening of the study).~3. Good general health as determined by the discretion of investigator.~4. Expressed interest and availability to fulfill the study requirements.~5. Agrees not to participate in another clinical trial at any time during the study period.~6. Agrees to remain in the study area for the entire duration of the study.~7. Willing to allow storage and future use of biological samples for future research.~Exclusion Criteria:~1. History of any other COVID-19 investigational vaccination.~2. Confirmed SARS-CoV-2 at the time of screening using RT-PCR and ELISA method.~3. Temperature \>38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days prior to each dose of vaccine.~4. Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrollment or expects to receive an investigational agent during the study period.~5. Receipt of any licensed vaccine within four weeks before enrollment in this study.~6. Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past.~7. Receipt of immunoglobulin or other blood products within the three months prior to vaccination in this study.~8. Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.~9. Long-term use (\>2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed).~10. Any history of hereditary angioedema or idiopathic angioedema.~11. Any history of anaphylaxis in relation to vaccination.~12. History of congenital diseases.~13. Any history of albumin-intolerance.~14. History of any cancer.~15. History of psychiatric severe conditions likely to affect participation in the study.~16. A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venepuncture.~17. Any other serious chronic illness requiring hospital specialist supervision.~18. Respiratory diseases like severe acute respiratory syndrome (SARS), including mild asthma.~19. Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness~20. History of SARS-CoV-2 infection or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration.~21. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.~    Re-Vaccination Exclusion Criteria~22. Anaphylactic reaction following administration of the investigational vaccine.~23. Virologically confirmed cases of COVID-19

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Study vaccine (Type: EXPERIMENTAL): SARS-COV2 vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).